TECH - candlestick chart analysis of Bio-Techne Corp

Popular stocks today

ADM ALB AXTI BLK BOX CAH CIFR DBC LEVI MCHP RANI RMBS SIL SPY SQQQ TECH UUUU VTIP VWO WYNN

Membership
- Log In
- Log Out
- Sign Up
- About HotCandlestick
- Benefits
- Help
Candlestick Charts
Chart Education
Trading Tools
Opportunities
External Links

Official PayPal Seal

As Seen In...

The Complete Guide to Using Candlestick Charting: How to Earn High Rates of Return safely

TECH Earnings: *Wed 6-MAY-2026

End of day quotes updated Fri Apr 17 15:47 CST
🏠

⎙

🔍

◄ Daily Pattern ► ◄ Weekly Pattern ► ◄ Monthly Pattern ► ◄ Quarterly Pattern ►
Bullish Harami Bullish Harami Bullish Doji Star Bullish Three Outside Up
30-Mar-2026 14-Nov-2025 30-May-2025 31-Mar-2021
-32.6 strength -143.8 strength 65.1 strength -288 strength

TECH	SPY
3.3 6.6 13.3 13.3 0.7	1.2 4.5 9.2 9.2 4.1
% Price Gain WTD Performance (%) MTD Performance (%) QTD Performance (%) YTD Performance (%)
SPY tracks S&P 500 index.

TECH News
20-Mar-2026 1:33 PM CST - Yahoo Finance How Is Bio-Techne's Stock Performance Compared to Other Biotechnology Stocks Bio-Techne has underperformed other biotechnology stocks over the past year, yet analysts remain moderately optimistic about the stock's growth potential.
13-Mar-2026 3:03 PM CST - Yahoo Finance Is Bio-Techne Stock a Buy, Sell, or Hold After a Wealth Manager Dumps Its Entire Stake? Bio-Techne develops specialized reagents and diagnostic solutions for global research and clinical markets in the life sciences sector.
4-Mar-2026 5:45 AM CST - Yahoo Finance 3 Reasons to Avoid TECH and 1 Stock to Buy Instead Bio-Techne trades at $56.99 and has moved in lockstep with the market. Its shares have returned 7.7% over the last six months while the S&P 500 has gained 5.7%.
28-Feb-2026 2:57 AM CST - Nasdaq Bio-Techne Rings the Closing Bell Techne Corporation (Nasdaq: TECH), a global provider of life science tools, reagents and diagnostic products, visits the Nasdaq MarketSite in Times Square as part of the company's 50th anniversary celebrations.
24-Feb-2026 2:53 PM CST - Yahoo Finance Bio-Techne Corporation (TECH) Carries Attractive FY27 Organic Growth Projections Bio-Techne Corporation (NASDAQ:TECH) is one of the 10 best life sciences stocks to buy according to hedge funds. On February 5, Daniel Arias from Stifel Nicolaus reaffirmed his Hold rating on Bio-Techne Corporation (NASDAQ:TECH).
19-Feb-2026 2:25 AM CST - Yahoo Finance Evaluating Bio-Techne (TECH) After Ella's CE-IVD Milestone And Diagnostics Growth Prospects CE-IVD certification puts Ella in focus for Bio-Techne investors Bio-Techne (TECH) just secured CE-IVD marking for its Ella benchtop immunoassay platform in the European Union, opening the door for clinical labs and assay developers to adopt the system.
11-Feb-2026 1:03 PM CST - Yahoo Finance There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings Soft earnings didn't appear to concern Bio-Techne Corporation's ( NASDAQ:TECH ) shareholders over the last week. We
11-Feb-2026 8:48 AM CST - Yahoo Finance Bio-Techne Announces Changes to its Leadership Team Bio-Techne Corporation (NASDAQ: TECH) today announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1,
4-Feb-2026 12:31 PM CST - Seeking Alpha Bio-Techne signals mid-single-digit underlying growth for fiscal 2026, with margin expansion and cell therapy normalization ahead Q2 2026 Management View CEO Kim Kelderman reported that "our second quarter performance was largely in line with our expectations. Continued strength from our large pharma customers was offset by a soft yet improving biotech end market and a soft but stable U.

Disclaimer Privacy Contact

Copyright © 2001-2026, All rights reserved.
HotCandlestick.com, LLC

TECH News
20-Mar-2026 1:33 PM CST - Yahoo Finance How Is Bio-Techne's Stock Performance Compared to Other Biotechnology Stocks Bio-Techne has underperformed other biotechnology stocks over the past year, yet analysts remain moderately optimistic about the stock's growth potential.
13-Mar-2026 3:03 PM CST - Yahoo Finance Is Bio-Techne Stock a Buy, Sell, or Hold After a Wealth Manager Dumps Its Entire Stake? Bio-Techne develops specialized reagents and diagnostic solutions for global research and clinical markets in the life sciences sector.
4-Mar-2026 5:45 AM CST - Yahoo Finance 3 Reasons to Avoid TECH and 1 Stock to Buy Instead Bio-Techne trades at $56.99 and has moved in lockstep with the market. Its shares have returned 7.7% over the last six months while the S&P 500 has gained 5.7%.
28-Feb-2026 2:57 AM CST - Nasdaq Bio-Techne Rings the Closing Bell Techne Corporation (Nasdaq: TECH), a global provider of life science tools, reagents and diagnostic products, visits the Nasdaq MarketSite in Times Square as part of the company's 50th anniversary celebrations.
24-Feb-2026 2:53 PM CST - Yahoo Finance Bio-Techne Corporation (TECH) Carries Attractive FY27 Organic Growth Projections Bio-Techne Corporation (NASDAQ:TECH) is one of the 10 best life sciences stocks to buy according to hedge funds. On February 5, Daniel Arias from Stifel Nicolaus reaffirmed his Hold rating on Bio-Techne Corporation (NASDAQ:TECH).
19-Feb-2026 2:25 AM CST - Yahoo Finance Evaluating Bio-Techne (TECH) After Ella's CE-IVD Milestone And Diagnostics Growth Prospects CE-IVD certification puts Ella in focus for Bio-Techne investors Bio-Techne (TECH) just secured CE-IVD marking for its Ella benchtop immunoassay platform in the European Union, opening the door for clinical labs and assay developers to adopt the system.
11-Feb-2026 1:03 PM CST - Yahoo Finance There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings Soft earnings didn't appear to concern Bio-Techne Corporation's ( NASDAQ:TECH ) shareholders over the last week. We
11-Feb-2026 8:48 AM CST - Yahoo Finance Bio-Techne Announces Changes to its Leadership Team Bio-Techne Corporation (NASDAQ: TECH) today announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1,
4-Feb-2026 12:31 PM CST - Seeking Alpha Bio-Techne signals mid-single-digit underlying growth for fiscal 2026, with margin expansion and cell therapy normalization ahead Q2 2026 Management View CEO Kim Kelderman reported that "our second quarter performance was largely in line with our expectations. Continued strength from our large pharma customers was offset by a soft yet improving biotech end market and a soft but stable U.